Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (Diluted Average) (2023 - 2026)

Perspective Therapeutics' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $103.6 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 43.18% to $103.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $103.6 million, a 43.18% increase, with the full-year FY2025 number at $73.8 million, up 14.57% from a year prior.
  • Shares Outstanding (Diluted Average) hit $103.6 million in Q1 2026 for Perspective Therapeutics, up from $73.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CATX hit a ceiling of $228.6 million in Q1 2023 and a floor of $26.8 million in Q4 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $73.2 million across 4 years, with a median of $70.6 million in 2024.
  • The widest YoY moves for Shares Outstanding (Diluted Average): up 151.75% in 2024, down 78.34% in 2024.
  • Tracing CATX's Shares Outstanding (Diluted Average) over 4 years: stood at $26.8 million in 2023, then surged by 140.72% to $64.4 million in 2024, then grew by 14.57% to $73.8 million in 2025, then soared by 40.36% to $103.6 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CATX at $103.6 million in Q1 2026, $73.8 million in Q4 2025, and $74.3 million in Q3 2025.